INZY News and Press, Inozyme Pharma Inc. From 05/26/22

Jefferies has initiated Inozyme (INZY) at hold saying proof-of-concept data on lead asset INZ-701 for two rare abnormal mineralization disorders. The firm has a $5 price target (~25% upside based on Wednesday's closing price). For further details see: Inozyme initiated at hold at Jeffer...

Inozyme Pharma press release (NASDAQ:INZY): Q1 GAAP EPS of -$0.71 beats by $0.11. Cash, cash equivalents, and investments were $97.8 million as of March 31, 2022. For further details see: Inozyme Pharma GAAP EPS of -$0.71 beats by $0.11

– Recently reported positive preliminary biomarker and safety data from ongoing Phase 1/2 clinical trial of INZ-701 in ENPP1 Deficiency – – Preliminary biomarker and safety data from ongoing Phase 1/2 trial of INZ-701 in ABCC6 Deficiency on track for the secon...

Gainers: Cyngn (CYN) +70%. Sky Harbour Group (SKYH) +28%. Redbox Entertainment (RDBX) +25%. Wrap Technologies (WRAP) +18%. Inozyme Pharma (INZY) +16%. MedAvail Holdings (MDVL) +14%. Red Cat Holdings (OTCQB:RCAT) +13%. Pulse Biosciences (PLSE) +12%. United Airlines Holdings (UAL) +11%. Alpha T...

Shares of Inozyme Pharma surged 17% on Thursday after SEC filings indicated stock purchases by company executives and a director. On April 19, CEO Axel Bolte bought 67,750 shares at a price of $3.69 for a purchase price of ~250K. On the same date, CFO Sanjay Subramanian and COO Henr...

Gainers: Inozyme Pharma (INZY) +15%. Clarus Therapeutics (CRXT) +10%. MedAvail (MDVL) +5%. Syros Pharmaceuticals (SYRS) +5%. Magenta Therapeutics (MGTA) +4%. Losers: AlloVir (ALVR) -10%. Rite Aid (RAD) -9%. Windtree Therapeutics (WINT) -7...

Gainers: Lexaria Bioscience (LEXX) +23%. Rite Aid (RAD) +14%. Inozyme Pharma (INZY) +12%. Finch Therapeutics (FNCH) +11%. Valneva (VALN) +9%. Losers: Protagonist Therapeutics (PTGX) -23%. Lixte Biotechnology (LIXT) -10%. Biofrontera (BFRI) ...

Inozyme Pharma (NASDAQ:INZY) has priced offering of 16,276,987 shares of its common stock at $3.69 per share and to certain investors in lieu of common stock, pre-funded warrants to purchase 3,523,013 shares of common stock at $3.6899 per pre-funded warrant, for aggregate gross proceeds of ~$...

BOSTON, April 14, 2022 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of abnormal mineralization, today announced the pricing of an underwritten offering of 16,276,987 shares of...

- First patient dosed in Phase 1/2 clinical trial in ABCC6 Deficiency – - Preliminary biomarker and safety data from Phase 1/2 clinical trial in ABCC6 Deficiency expected in the second quarter of 2022 – - Second cohort in Phase 1/2 clinical trial in ENPP1 D...